✦ LIBER ✦

Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer

✍ Scribed by Liora Navon; Amira Morag

Book ID: 113905650
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 244 KB
Volume: 58
Category: Article
ISSN: 0277-9536
DOI: 10.1016/j.socscimed.2003.08.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Follow-Up of Patients Treated

Long-Term Follow-Up of Patients Treated with Intermittent Hormone Therapy for Advanced Prostate Cancer

✍ George Hruby; Howard Gurney; Sandra Turner; Martin Berry; Paul Harnett; Val Gebs 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Efficacy of primary hormone therapy for

Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up

✍ HIDEYUKI AKAZA; YUKIO HOMMA; MICHIYUKI USAMI; YOSHIHIKO HIRAO; TOMOYASU TSUSHIMA 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

PS2 Late breaking Adding bicalutamide 15

PS2 Late breaking Adding bicalutamide 150mg to standard care for localised or locally advanced prostate cancer: results from the largest hormonal therapy trial ever conducted in prostate cancer patients, at over 7 years' follow up

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Estimating survival gain for economic ev

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

✍ N. Neymark; I. Adriaenssen; T. Gorlia; S. Caleo; M. Bolla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival t